BNGO Quote, Financials, Valuation and Earnings

Bruker Corp. has a net margin of -115.42% compared to Bionano Genomics, Inc.'s net margin of -6.8%. Bionano Genomics, Inc.'s return on equity of -84.77% beat Bruker Corp.'s return on equity of -1.2%.

Bionano Genomics, Inc. has a consensus price target of $7.50, signalling upside risk potential of 377.71%. On the other hand Bruker Corp. has an analysts' consensus of $51.79 which suggests that it could grow by 6.18%. Given that Bionano Genomics, Inc. has higher upside potential than Bruker Corp., analysts believe Bionano Genomics, Inc. is more attractive than Bruker Corp..

Bionano Genomics, Inc. has a beta of 2.336, which suggesting that the stock is 133.592% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.405%.

Bionano Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.41% to investors and pays a quarterly dividend of $0.05 per share. Bionano Genomics, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bionano Genomics, Inc. quarterly revenues are $7.4M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Bionano Genomics, Inc.'s net income of -$8.5M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Bionano Genomics, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics, Inc. is 0.18x versus 2.15x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of -115.42% compared to Bionano Genomics, Inc.'s net margin of -5.98%. Bionano Genomics, Inc.'s return on equity of -84.77% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Bionano Genomics, Inc. has a consensus price target of $7.50, signalling upside risk potential of 377.71%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 165.15%. Given that Bionano Genomics, Inc. has higher upside potential than Harvard Bioscience, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Harvard Bioscience, Inc..

Bionano Genomics, Inc. has a beta of 2.336, which suggesting that the stock is 133.592% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.123%.

Bionano Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.

Bionano Genomics, Inc. quarterly revenues are $7.4M, which are smaller than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Bionano Genomics, Inc.'s net income of -$8.5M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Bionano Genomics, Inc.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics, Inc. is 0.18x versus 0.38x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kestra Medical Technologies Ltd. has a net margin of -115.42% compared to Bionano Genomics, Inc.'s net margin of -145.29%. Bionano Genomics, Inc.'s return on equity of -84.77% beat Kestra Medical Technologies Ltd.'s return on equity of -105.99%.

Bionano Genomics, Inc. has a consensus price target of $7.50, signalling upside risk potential of 377.71%. On the other hand Kestra Medical Technologies Ltd. has an analysts' consensus of $29.14 which suggests that it could grow by 4.05%. Given that Bionano Genomics, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Bionano Genomics, Inc. is more attractive than Kestra Medical Technologies Ltd..

Bionano Genomics, Inc. has a beta of 2.336, which suggesting that the stock is 133.592% more volatile than S&P 500. In comparison Kestra Medical Technologies Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bionano Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics, Inc. pays -- of its earnings as a dividend. Kestra Medical Technologies Ltd. pays out 1.45% of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bionano Genomics, Inc. quarterly revenues are $7.4M, which are smaller than Kestra Medical Technologies Ltd. quarterly revenues of $22.6M. Bionano Genomics, Inc.'s net income of -$8.5M is higher than Kestra Medical Technologies Ltd.'s net income of -$32.8M. Notably, Bionano Genomics, Inc.'s price-to-earnings ratio is -- while Kestra Medical Technologies Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics, Inc. is 0.18x versus 19.37x for Kestra Medical Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Precipio, Inc. has a net margin of -115.42% compared to Bionano Genomics, Inc.'s net margin of -1.17%. Bionano Genomics, Inc.'s return on equity of -84.77% beat Precipio, Inc.'s return on equity of -10.15%.

Bionano Genomics, Inc. has a consensus price target of $7.50, signalling upside risk potential of 377.71%. On the other hand Precipio, Inc. has an analysts' consensus of -- which suggests that it could fall by -17.75%. Given that Bionano Genomics, Inc. has higher upside potential than Precipio, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Precipio, Inc..

Bionano Genomics, Inc. has a beta of 2.336, which suggesting that the stock is 133.592% more volatile than S&P 500. In comparison Precipio, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.543%.

Bionano Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precipio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics, Inc. pays -- of its earnings as a dividend. Precipio, Inc. pays out -- of its earnings as a dividend.

Bionano Genomics, Inc. quarterly revenues are $7.4M, which are larger than Precipio, Inc. quarterly revenues of $6.8M. Bionano Genomics, Inc.'s net income of -$8.5M is lower than Precipio, Inc.'s net income of -$79K. Notably, Bionano Genomics, Inc.'s price-to-earnings ratio is -- while Precipio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics, Inc. is 0.18x versus 1.58x for Precipio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.